The greater risk of developing contralateral breast cancer in BRCA1/2 mutation carriers compared to women with sporadic cancer supports the necessity of RRM for the unaffected side of breast for BRCA1/2 mutation carriers. Here, BRCA1 is linked to breast carcinoma.